| Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up E Celik, HM Ozkaya, BC Poyraz, T Saglam, P Kadioglu Endocrine 62, 692-700, 2018 | 35 | 2018 |
| Comparison of attention for cancer research on social media versus academia: An altmetric score analysis E Celik, M Dokur, B Börkü Uysal, N Şengül Samancı, FH Demirelli Akademi Doktorlar Yayınevi, 2020 | 16 | 2020 |
| Optic neuritis related to atezolizumab treatment in a patient with metastatic non–small-cell lung cancer N Sengul Samanci, T Ozan, E Çelik, FH Demirelli JCO oncology practice 16 (2), 96-98, 2020 | 11 | 2020 |
| The relationship between symptom severity and caregiver burden in cancer patients under palliative care: A cross-sectional study E Celik, MS Aslan, N Sengul Samanci, M Karadag, T Saglam, ... Journal of Palliative Care 37 (1), 48-54, 2022 | 9 | 2022 |
| The top 100 cited articles in lung cancer–a bibliometric analysis N Samanci, E Celik Contemporary Oncology/Współczesna Onkologia 24 (1), 17-28, 2020 | 9 | 2020 |
| Patients with acromegaly might not be at higher risk for dopamine agonist-induced impulse control disorders than those with prolactinomas HM Ozkaya, S Sahin, OP Korkmaz, E Durcan, HR Sahin, E Celik, ... Growth Hormone & IGF Research 55, 101356, 2020 | 7 | 2020 |
| The most cited articles on cancer immunotherapy: An update study E Celik, M Dokur BAKIS Productions LTD, 2020 | 7 | 2020 |
| Loss of skeletal muscle area and fat-free mass during dabrafenib/trametinib and vemurafenib/cobimetinib treatments in patients with BRAF-mutant metastatic malignant melanoma NS Samanci, E Çelik, O Bagcilar, BC Erol, E Bicki, K Oruc, S Bedir, ... Melanoma Research 30 (5), 477-483, 2020 | 6 | 2020 |
| Immune-related adverse events associated with immune checkpoint inhibitors in patients with cancer N Sengul Samanci, DI Cikman, K Oruc, S Bedir, E Çelik, E Degerli, ... Tumori Journal 107 (4), 304-310, 2021 | 5 | 2021 |
| The demographic characteristics, prognosis, and relationship with cancer subtypes of hospitalized COVID‐19 patients with malignancy: A single‐center experience E Değerli, S Derin, K Oruç, N Şengül Samancı, Ş Bedir, E Çelik, ... Journal of Medical Virology 93 (10), 5839-5845, 2021 | 4 | 2021 |
| Facial cutaneous metastasis of rectal adenocarcinoma NS Samanci, S Akdogan, E Celik, O Kutlu, OA Ulgen, FH Demirelli North Clin Istanb 8, 518-520, 2021 | 4 | 2021 |
| Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study B Bilgin, MAN Sendur, S Yucel, E Celik, DT Ozyukseler, M Ayhan, ... Journal of Cancer Research and Clinical Oncology 147, 2145-2152, 2021 | 4 | 2021 |
| Sarcopenia assessment by new EWGSOP2 criteria for predicting chemotherapy dose-limiting toxicity in patients with gastrointestinal tract tumors E Celik, V Suzan, NS Samanci, AA Suzan, M Karadag, S Sahin, MS Aslan, ... European Geriatric Medicine, 1-8, 2022 | 3 | 2022 |
| Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study P Gursoy, AM Tatli, D Erdem, E Goker, E Celik, NS Demirci, A Sakin, ... Journal of Cancer Research and Clinical Oncology 149 (2), 865-875, 2023 | 2 | 2023 |
| Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group C Erol, MAN Sendur, I Bilgetekin, DB Garbioglu, J Hamdard, S Akbas, ... Journal of cancer research and therapeutics 18 (Suppl 2), S347-S353, 2022 | 2 | 2022 |
| Breast cancer to thyroid gland: An unconventional metastatic site E Celik, T Ozturk, NS Samanci, NS Demirci, B Akovali, FH Demirelli Journal of Cancer Research and Therapeutics 18 (3), 788-791, 2022 | 1 | 2022 |
| Risk of Malnutrition and Its Effects on the Quality of Life of Hospitalized Cancer Patients. E Çelik, MŞ Aslan, N ŞENGÜL SAMANCI, M Karadağ, V Suzan, ... Namik Kemal Tip Dergisi 9 (1), 2021 | 1 | 2021 |
| Response Rates and Predictive Factors of Pathological Complete Response to Neoadjuvant Chemotherapy in Luminal B HER2 Negative Breast Cancer NS Samanci, RU Gursu, Y Bozkaya, E Arslan, MB Ulusan, FDC Trablus, ... Eurasian J Med Investig 5, 476-80, 2021 | 1 | 2021 |
| Hospitalize Kanser Hastalarında Malnütrisyon Riski ve Yaşam Kalitesine Etkisi E ÇELİK, MŞ ASLAN, NŞ SAMANCI, M KARADAĞ, V SUZAN, YÇ ÇELİK, ... Namık Kemal Tıp Dergisi 9 (1), 84-90, 2021 | 1 | 2021 |
| The relationship between eGFR and capecitabine efficacy/toxicity in metastatic breast cancer E Celik, NS Samanci, M Karadag, NS Demirci, FH Demirelli, M Ozguroglu Medical Oncology 38, 1-10, 2021 | 1 | 2021 |
